🇺🇸 FDA

Company profile · Sponsor

Aurinia

Aurinia Pharmaceuticals

AUPH · NYSE pharma EDMONTON, A0, USA
Pipeline
14
Drugs
1
Patents
7

Quick answer

Aurinia (AUPH) is a pharma company. headquartered in EDMONTON, A0, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 1 drug, and 7 patents to this profile..

Company facts

Ticker AUPH
Exchange NYSE
Company type pharma
Headquarters EDMONTON, A0, USA
SEC CIK 0001600620

Pipeline (14)

Search pipeline →

  1. 0.05% Voclosporin Ophthalmic Solution (VOS)

    Aurinia

    Dry Eye Syndrome

    phase 3 small molecule completed

    1 trial

  2. Voclosporin

    Aurinia

    Adolescent Lupus Nephritis

    phase 3 small molecule terminated

    2 trials

  3. Voclosporin

    Aurinia

    Lupus Nephritis

    phase 3 small molecule completed

    3 trials

  4. voclosporin

    Aurinia

    Psoriasis

    phase 3 small molecule completed

    3 trials

  5. voclosporin

    Aurinia

    Renal Transplantation

    phase 3 small molecule terminated

    1 trial

  6. AUR200, Isotone Natriumchloridlösung 0,9 % Braun Injektionslösung

    Aurinia

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  7. Aritinercept

    Aurinia

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  8. Voclosporin

    Aurinia

    Covid19

    phase 2 small molecule completed

    1 trial

  9. Voclosporin

    Aurinia

    Focal Segmental Glomerulosclerosis

    phase 2 small molecule terminated

    1 trial

  10. Voclosporin

    Aurinia

    Kidney Diseases

    phase 2 small molecule completed

    1 trial

  11. Voclosporin High Dose

    Aurinia

    Lupus Nephritis

    phase 2 small molecule completed

    1 trial

  12. Voclosporin Ophthalmic Solution

    Aurinia

    Dry Eye

    phase 2 small molecule completed

    1 trial

  13. Simvastatin

    Aurinia

    Drug-drug Interaction

    phase 1 small molecule completed

    1 trial

  14. Voclosporin

    Aurinia

    Volunteers

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. voclosporin

    LUVENIQ

    ORAL approved

    L04AD03

Patents (7)

Search patents →

  1. US 11622991

    Protocol for treatment of lupus nephritis

    Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10973871

    Ophthalmic compositions

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10472394

    Cyclosporine analogue mixtures and their use as immunomodulating agents

    Expires Mon Nov 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10286036

    Protocol for treatment of lupus nephritis

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10265375

    Ophthalmic compositions

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9765119

    Cyclosporine analogue mixtures and their use as immunomodulating agents

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9017725

    Topical drug delivery systems for ophthalmic use

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aurinia?

Aurinia (AUPH) is a pharma company. headquartered in EDMONTON, A0, USA. listed on NYSE. NovaPharmaNews links 14 pipeline programs, 1 drug, and 7 patents to this profile..

What pipeline programs does Aurinia sponsor?

We track 14 ClinicalTrials.gov-linked programs for Aurinia, including 0.05% Voclosporin Ophthalmic Solution (VOS) and 13 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aurinia company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.